Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma

BACKGROUND: We aimed to evaluate the clinical outcomes of molecular glioblastoma (mGBM) as compared to histological GBM (hGBM) and to determine the prognostic impact of TERT mutation, EGFR amplification, and CDKN2A/B deletion on isocitrate dehydrogenase (IDH)-wildtype GBM. METHODS: IDH-wildtype GBM...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neurooncol Adv
Main Authors: Ma, Sirui, Rudra, Soumon, Campian, Jian L, Dahiya, Sonika, Dunn, Gavin P, Johanns, Tanner, Goldstein, Michael, Kim, Albert H, Huang, Jiayi
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7668466/
https://ncbi.nlm.nih.gov/pubmed/33235995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa126
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares